Epigenomics (EPGNF)

[jupp]

Epigenomics receives notification of priority review status and acceptance for filing by FDA of PMA application for Epi proColon®

21.02.2013

Berlin, Germany, and Seattle, WA, U.S.A. - Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, announced today that the United States Food & Drug Administration (FDA) accepted its Premarket Approval (PMA) application for Epi proColon®. The agency concluded that all information needed for the substantive review is included and has granted priority review status to the application. Epi proColon® is Epigenomics’ blood-based test for the detection of colorectal cancer (CRC).